StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11−0.05 (-2.31%)

Close on Nov 17, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Rocket Pharmaceuticals's enterprise value was -$12.04M on Nov 11, 2026, against $147.27M a year earlier. Over the last 5 years it ranged from -$56.65M to $2.26B, with a median of $742.89M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$12.04M-107.7%
2025Dec 31, 2025$157.01M-82.7%
2024Dec 31, 2024$909.64M-59.8%
2023Dec 29, 2023$2.26B+121.8%
2022Dec 30, 2022$1.02B+3.6%
2021Dec 31, 2021$985.28M-64.8%
2020Dec 31, 2020$2.80B+241.1%
2019Dec 31, 2019$820.42M+90.4%
2018Dec 31, 2018$430.88M–
2017Dec 29, 2017-$32.07M-220.2%
2016Dec 30, 2016$26.69M-85.2%
2015Dec 31, 2015$180.86M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?